CannBioRx Sale Purchase Of Stock vs End Period Cash Flow Analysis

ATNFW Stock

USD 0.01 0.000012 0.15%

CannBioRx Life financial indicator trend analysis is way more than just evaluating CannBioRx Life Sciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CannBioRx Life Sciences is a good investment. Please check the relationship between CannBioRx Life Sale Purchase Of Stock and its End Period Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CannBioRx Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.

Sale Purchase Of Stock vs End Period Cash Flow

Sale Purchase Of Stock vs End Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CannBioRx Life Sciences Sale Purchase Of Stock account and End Period Cash Flow. At this time, the significance of the direction appears to have no relationship.

The correlation between CannBioRx Life's Sale Purchase Of Stock and End Period Cash Flow is 0.08. Overlapping area represents the amount of variation of Sale Purchase Of Stock that can explain the historical movement of End Period Cash Flow in the same time period over historical financial statements of CannBioRx Life Sciences, assuming nothing else is changed. The correlation between historical values of CannBioRx Life's Sale Purchase Of Stock and End Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Sale Purchase Of Stock of CannBioRx Life Sciences are associated (or correlated) with its End Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when End Period Cash Flow has no effect on the direction of Sale Purchase Of Stock i.e., CannBioRx Life's Sale Purchase Of Stock and End Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.08

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Sale Purchase Of Stock

End Period Cash Flow

Most indicators from CannBioRx Life's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CannBioRx Life Sciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CannBioRx Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.

Selling General Administrative is likely to drop to about 7.6 M in 2024. Tax Provision is likely to climb to about (3.1 M) in 2024

	2021	2022	2023	2024 (projected)
Research Development	3.9M	2.4M	2.8M	2.7M
Depreciation And Amortization	116.3K	109.0K	105.7K	101.1K

Research Development Depreciation And Amortization

CannBioRx Life fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Cash And Short Term Investments	Capital Surpluse	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Other Current Liab	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Stockholder Equity	Short Long Term Debt Total	Accounts Payable	Net Receivables	Good Will	Common Stock Total Equity	Inventory	Other Current Assets
Total Assets		0.25	0.43	0.09	0.87	0.69	0.44	0.13	0.88	0.85	0.28	0.03	0.08	0.05	-0.08	0.17	-0.08	0.22	0.03	0.13	0.1	0.22	0.24	0.22	0.34	0.07
Total Current Liabilities	0.25		0.84	-0.52	-0.21	0.57	0.97	0.72	0.52	-0.25	0.89	-0.17	0.62	-0.61	-0.82	0.64	-0.8	-0.2	0.75	-0.3	0.08	0.86	-0.11	-0.14	0.68	0.75
Total Stockholder Equity	0.43	0.84		-0.24	-0.07	0.53	0.91	0.55	0.63	-0.1	0.78	-0.05	0.47	-0.37	-0.64	0.41	-0.64	0.14	0.55	-0.06	0.03	0.66	0.18	0.23	0.67	0.48
Retained Earnings	0.09	-0.52	-0.24		0.25	-0.63	-0.42	-0.72	-0.18	0.29	-0.37	0.39	-0.67	0.98	0.89	-0.1	0.89	0.89	-0.94	0.91	0.45	-0.42	0.89	0.7	0.22	-0.8
Cash And Short Term Investments	0.87	-0.21	-0.07	0.25		0.46	-0.04	-0.15	0.6	1.0	-0.13	0.03	-0.16	0.27	0.28	-0.11	0.29	0.19	-0.28	0.18	0.04	-0.15	0.17	0.14	-0.02	-0.2
Capital Surpluse	0.69	0.57	0.53	-0.63	0.46		0.65	0.56	0.83	0.42	0.43	-0.15	0.46	-0.68	-0.71	0.24	-0.71	-0.46	0.71	-0.51	-0.17	0.43	-0.44	-0.3	0.08	0.56
Total Liab	0.44	0.97	0.91	-0.42	-0.04	0.65		0.69	0.65	-0.08	0.88	-0.16	0.59	-0.52	-0.76	0.64	-0.74	-0.06	0.67	-0.22	0.11	0.85	0.0	0.04	0.72	0.68
Total Current Assets	0.13	0.72	0.55	-0.72	-0.15	0.56	0.69		0.22	-0.22	0.8	-0.77	0.99	-0.71	-0.81	0.15	-0.76	-0.37	0.78	-0.74	-0.52	0.78	-0.47	-0.18	0.29	0.92
Short Term Debt	0.88	0.52	0.63	-0.18	0.6	0.83	0.65	0.22		0.59	0.34	0.22	0.11	-0.29	-0.42	0.43	-0.43	-0.02	0.37	0.03	0.25	0.38	0.04	0.01	0.33	0.18
Common Stock	0.85	-0.25	-0.1	0.29	1.0	0.42	-0.08	-0.22	0.59		-0.18	0.08	-0.22	0.31	0.32	-0.11	0.32	0.2	-0.32	0.22	0.07	-0.2	0.19	0.14	-0.04	-0.25
Other Current Liab	0.28	0.89	0.78	-0.37	-0.13	0.43	0.88	0.8	0.34	-0.18		-0.47	0.75	-0.4	-0.63	0.4	-0.59	-0.02	0.56	-0.31	-0.18	0.82	0.05	0.05	0.78	0.81
Net Debt	0.03	-0.17	-0.05	0.39	0.03	-0.15	-0.16	-0.77	0.22	0.08	-0.47		-0.85	0.28	0.29	0.29	0.22	0.17	-0.3	0.65	0.73	-0.43	0.36	0.02	-0.04	-0.66
Cash	0.08	0.62	0.47	-0.67	-0.16	0.46	0.59	0.99	0.11	-0.22	0.75	-0.85		-0.64	-0.72	0.05	-0.67	-0.32	0.7	-0.73	-0.58	0.75	-0.46	-0.15	0.24	0.88
Non Current Assets Total	0.05	-0.61	-0.37	0.98	0.27	-0.68	-0.52	-0.71	-0.29	0.31	-0.4	0.28	-0.64		0.94	-0.19	0.95	0.83	-0.98	0.84	0.35	-0.47	0.83	0.64	0.15	-0.76
Non Currrent Assets Other	-0.08	-0.82	-0.64	0.89	0.28	-0.71	-0.76	-0.81	-0.42	0.32	-0.63	0.29	-0.72	0.94		-0.36	0.99	0.62	-0.99	0.71	0.24	-0.68	0.61	0.43	-0.15	-0.82
Common Stock Shares Outstanding	0.17	0.64	0.41	-0.1	-0.11	0.24	0.64	0.15	0.43	-0.11	0.4	0.29	0.05	-0.19	-0.36		-0.34	0.08	0.26	0.21	0.76	0.66	0.13	0.08	0.61	0.17
Short Term Investments	-0.08	-0.8	-0.64	0.89	0.29	-0.71	-0.74	-0.76	-0.43	0.32	-0.59	0.22	-0.67	0.95	0.99	-0.34		0.64	-0.99	0.69	0.23	-0.62	0.61	0.46	-0.12	-0.78
Non Current Liabilities Total	0.22	-0.2	0.14	0.89	0.19	-0.46	-0.06	-0.37	-0.02	0.2	-0.02	0.17	-0.32	0.83	0.62	0.08	0.64		-0.72	0.82	0.41	-0.02	0.91	0.91	0.49	-0.56
Other Stockholder Equity	0.03	0.75	0.55	-0.94	-0.28	0.71	0.67	0.78	0.37	-0.32	0.56	-0.3	0.7	-0.98	-0.99	0.26	-0.99	-0.72		-0.78	-0.32	0.58	-0.7	-0.54	0.03	0.82
Short Long Term Debt Total	0.13	-0.3	-0.06	0.91	0.18	-0.51	-0.22	-0.74	0.03	0.22	-0.31	0.65	-0.73	0.84	0.71	0.21	0.69	0.82	-0.78		0.72	-0.27	0.88	0.58	0.33	-0.79
Accounts Payable	0.1	0.08	0.03	0.45	0.04	-0.17	0.11	-0.52	0.25	0.07	-0.18	0.73	-0.58	0.35	0.24	0.76	0.23	0.41	-0.32	0.72		0.1	0.47	0.28	0.35	-0.5
Net Receivables	0.22	0.86	0.66	-0.42	-0.15	0.43	0.85	0.78	0.38	-0.2	0.82	-0.43	0.75	-0.47	-0.68	0.66	-0.62	-0.02	0.58	-0.27	0.1		-0.11	0.06	0.64	0.68
Good Will	0.24	-0.11	0.18	0.89	0.17	-0.44	0.0	-0.47	0.04	0.19	0.05	0.36	-0.46	0.83	0.61	0.13	0.61	0.91	-0.7	0.88	0.47	-0.11		0.74	0.61	-0.51
Common Stock Total Equity	0.22	-0.14	0.23	0.7	0.14	-0.3	0.04	-0.18	0.01	0.14	0.05	0.02	-0.15	0.64	0.43	0.08	0.46	0.91	-0.54	0.58	0.28	0.06	0.74		0.43	-0.42
Inventory	0.34	0.68	0.67	0.22	-0.02	0.08	0.72	0.29	0.33	-0.04	0.78	-0.04	0.24	0.15	-0.15	0.61	-0.12	0.49	0.03	0.33	0.35	0.64	0.61	0.43		0.3
Other Current Assets	0.07	0.75	0.48	-0.8	-0.2	0.56	0.68	0.92	0.18	-0.25	0.81	-0.66	0.88	-0.76	-0.82	0.17	-0.78	-0.56	0.82	-0.79	-0.5	0.68	-0.51	-0.42	0.3

Click cells to compare fundamentals

CannBioRx Life Account Relationship Matchups

CannBioRx Life fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	51.9M	55.5M	62.7M	19.7M	5.3M	5.0M
Total Current Liabilities	9.6M	21.4M	19.7M	5.7M	5.1M	8.6M
Total Stockholder Equity	38.6M	30.3M	39.3M	11.3M	(127.7K)	(121.3K)
Retained Earnings	(37.5M)	(48.4M)	(68.7M)	(107.4M)	(127.3M)	(121.0M)
Cash And Short Term Investments	83.4K	2.1M	8.2M	7.0M	2.0M	1.9M
Total Liab	13.3M	25.2M	23.4M	8.3M	5.4M	5.1M
Total Current Assets	748.3K	4.0M	11.2M	8.9M	3.6M	4.0M
Common Stock	1.4K	2.6K	3.4K	375.0	54.0	51.3
Other Current Liab	2.0M	9.2M	17.2M	2.5M	1.9M	1.8M
Net Debt	3.4M	1.7M	(6.3M)	(5.6M)	(921.7K)	(967.8K)
Cash	83.4K	2.1M	8.2M	7.0M	2.0M	3.2M
Non Current Assets Total	51.1M	51.5M	51.5M	10.7M	1.6M	1.5M
Common Stock Shares Outstanding	29.0K	26.2M	82.5K	100.0K	379.1K	360.1K
Liabilities And Stockholders Equity	51.9M	55.5M	62.7M	19.7M	5.3M	5.0M
Non Current Liabilities Total	3.7M	3.8M	3.7M	2.6M	324.6K	308.4K
Other Stockholder Equity	75.9M	78.0M	107.2M	121.6M	130.1M	136.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for CannBioRx Stock Analysis

When running CannBioRx Life's price analysis, check to measure CannBioRx Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CannBioRx Life is operating at the current time. Most of CannBioRx Life's value examination focuses on studying past and present price action to predict the probability of CannBioRx Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CannBioRx Life's price. Additionally, you may evaluate how the addition of CannBioRx Life to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

CannBioRx Sale Purchase Of Stock vs End Period Cash Flow Analysis

Sale Purchase Of Stock vs End Period Cash Flow

Sale Purchase Of Stock vs End Period Cash Flow Correlation Analysis

Correlation Coefficient

Sale Purchase Of Stock

End Period Cash Flow

CannBioRx Life fundamental ratios Correlations

CannBioRx Life Account Relationship Matchups

High Positive Relationship

High Negative Relationship

CannBioRx Life fundamental ratios Accounts

Also Currently Popular

Additional Tools for CannBioRx Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Cash And Short Term Investments
Cash	+ 0.99	Total Current Assets
Short Term Investments	+ 0.99	Non Currrent Assets Other
Non Current Assets Total	+ 0.98	Retained Earnings
Total Liab	+ 0.97	Total Current Liabilities
Short Term Investments	+ 0.95	Non Current Assets Total

Other Stockholder Equity	- 0.99	Short Term Investments
Other Stockholder Equity	- 0.99	Non Currrent Assets Other
Other Stockholder Equity	- 0.98	Non Current Assets Total
Other Stockholder Equity	- 0.94	Retained Earnings
Cash	- 0.85	Net Debt
Other Current Assets	- 0.82	Non Currrent Assets Other